Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
EVP, Investments & CLO · Royalty Pharma plc · Class A Ordinary Shares
Open-market sale
$179K reported value · 100.0% of prior position
Disclosed 2 business days after execution (deadline: 2)
First recorded trade by this actor in this security
1 other actor traded the same direction within 14 days
No material company filing within 60 days after the trade
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 2 | Coyne Terrance P.EVP & CFO | Derivative conversion | C | — 10.0K sh | Nov 6, 2026 traded Nov 6, 2026 | |
| 5 | Hite ChristopherEVP & Chairman, Partnering | Grant or award | A | — 7,122 sh | Nov 6, 2026 traded Nov 4, 2026 | |
| 2 | Coyne Terrance P.EVP & CFO | Derivative conversion | C | — 100.0K sh | Nov 6, 2026 traded Nov 6, 2026 | |
| 2 | Coyne Terrance P.EVP & CFO | Derivative conversion | C | — 150.0K sh | Nov 6, 2026 traded Nov 6, 2026 | |
| 2 | Coyne Terrance P.EVP & CFO | Grant or award | A | — 7,122 sh | Nov 6, 2026 traded Nov 4, 2026 | |
| 2 | Urist MarshallEVP, Research & Investments | Derivative conversion | C | — 150.0K sh | Nov 6, 2026 traded Nov 6, 2026 | |
| 9 | Legorreta Pablo G.Director, CEO, Chairman of the Board | Grant or award | A | — 42.2K sh | Nov 6, 2026 traded Nov 4, 2026 | |
| 2 | Urist MarshallEVP, Research & Investments | Grant or award | A | — 5,341 sh | Nov 6, 2026 traded Nov 4, 2026 | |
| 6 | Urist MarshallEVP, Research & Investments | Derivative conversion | C | — 15.0K sh | Nov 6, 2026 traded Nov 6, 2026 | |
| 6 | Coyne Terrance P.EVP & CFO | Derivative conversion | C | — 15.0K sh | Nov 6, 2026 traded Nov 6, 2026 | |
| 18 | Urist MarshallEVP, Research & Investments | Open-market sale · 10b5-1 plan | SELL | $239K 4,126 sh | Sep 30, 2026 traded Sep 28, 2026 | |
| 9 | Bassler Bonnie LDirector | Grant or award | A | $37K 642 sh | Sep 30, 2026 traded Sep 30, 2026 | |
| 9 | Hite ChristopherEVP & Chairman, Partnering | Open-market sale · 10b5-1 plan | SELL | $231K 3,927 sh | Sep 24, 2026 traded Sep 22, 2026 | |
| 23 | Hite ChristopherEVP & Chairman, Partnering | Open-market sale · 10b5-1 plan | SELL | $5.62M 96.1K sh | Sep 24, 2026 traded Sep 22, 2026 | |
| 23 | Hite ChristopherEVP & Chairman, Partnering | Open-market sale · 10b5-1 plan | SELL | $6.00M 100.0K sh | Aug 19, 2026 traded Aug 18, 2026 | |
| 10 | Hite ChristopherEVP & Chairman, Partnering | Gift · 10b5-1 plan | G | — 16.8K sh | Aug 19, 2026 traded Aug 19, 2026 | |
| 21 | Coyne Terrance P.EVP & CFO | Open-market sale · 10b5-1 plan | SELL | $541K 9,230 sh | Aug 17, 2026 traded Aug 13, 2026 | |
| 18 | Coyne Terrance P.EVP & CFO | Open-market sale · 10b5-1 plan | SELL | $105K 1,772 sh | Aug 17, 2026 traded Aug 13, 2026 | |
| 5 | Coyne Terrance P.EVP & CFO | Gift | G | — 18.5K sh | Aug 7, 2026 traded Aug 7, 2026 | |
| 5 | Urist MarshallEVP, Research & Investments | Gift | G | — 3,000 sh | Aug 7, 2026 traded Aug 7, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $179,394
Lloyd George W. filed this Form 4 reporting a open-market sale of RPRX on Nov 19, 2025. It became public on Nov 21, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.